Streetbeat News

BNTC

Benitec Biopharma Inc.

Industry

Biotechnology

Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy; and BB-103 for the treatment of chronic hepatitis B virus infection. The company was incorporated in 1995 and is headquartered in Hayward, California.

Open

11.84

Mkt cap

291M

Volume

32K

High

12.90

P/E Ratio

-20.03

52-wk high

13.29

Low

11.84

Div yield

N/A

52-wk low

4.26

Wall Street analysts predict a significant upside of 127.3% for Benitec Biopharma (BNTC) based on average price targets. Positive earnings estimate revisions could support this potential increase.

Portfolio Pulse from

February 20, 2025 | 4:00 pm

Benitec Biopharma (BNTC) is experiencing a positive price trend, making it a potential choice for short-term investors. The stock has been identified as fundamentally sound and has passed a trading strategy-based screen.

Portfolio Pulse from

February 20, 2025 | 3:00 pm

Benitec Biopharma Inc. (NASDAQ: BNTC) released its Q2 2025 financial results and provided an operational update. The company safely treated the fifth subject in its BB-301 Phase 1b/2a clinical study and will present an interim update at the 2025 Muscular Dystrophy Association Conference.

Portfolio Pulse from

February 14, 2025 | 1:30 pm

Benitec Biopharma (BNTC) has experienced positive earnings estimate revisions recently, indicating potential strength in its stock. The company is also part of a robust industry, which may further support its stock performance.

Portfolio Pulse from

January 13, 2025 | 4:00 pm

Benitec Biopharma (BNTC) has shown recent price strength, making it a potentially profitable choice for investors seeking stocks with upward momentum.

Portfolio Pulse from

December 25, 2024 | 3:00 pm

Benitec Biopharma Inc. (NASDAQ: BNTC), a clinical-stage biotechnology company, will participate in upcoming investor conferences in December. The company focuses on gene therapy and genetic medicines using its proprietary ddRNAi platform.

Portfolio Pulse from

November 26, 2024 | 12:15 pm

Benitec Biopharma released its Q1 2025 financial results and provided an operational update, highlighting positive interim clinical study data for its BB-301 treatment.

Portfolio Pulse from

November 14, 2024 | 9:45 pm

Benitec Biopharma has filed with the SEC for a mixed shelf offering of up to $125 million. This move allows the company to raise capital through various financial instruments, which could be used for corporate purposes such as research and development, or to strengthen its balance sheet.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2024 | 9:09 pm

Oppenheimer has initiated coverage on Benitec Biopharma with an Outperform rating and set a price target of $35.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2024 | 9:12 am

Top Wall Street analysts have updated their price targets and ratings for several companies, including JPMorgan Chase, Nurix Therapeutics, V.F. Corporation, Affirm Holdings, Snap Inc., Wells Fargo, Benitec Biopharma, Boot Barn Holdings, Fastenal Company, and ArcBest Corporation. These changes reflect varying outlooks on the companies' future performance.

Portfolio Pulse from Avi Kapoor

October 14, 2024 | 2:29 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.